Traditionally, stock market corrections have been the perfect time for long-term-minded investors with ample cash on hand to ...

As is the case with many investors, the post-pandemic period really shifted my interest in growth stocks into overdrive. I ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

NNN REIT is a strong choice for income investors with solid AFFO growth, a high dividend yield, and robust fundamentals. Read ...

For greater potential upside, consider earlier-stage smid-cap biotech names. Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks ...

Fuchs SE's (FUPBY) fiscal 2024 results disappointed investors, causing a temporary stock decline. See why I continue to rate ...

But this year the MSCI China index has beaten its American equivalent by an impressive 20 percentage points, on the back of ...

Over the last 12 months, small-growth funds have returned 1.81%. On an annualized rate, they have returned 1.17% over the ...

That's still just the beginning. Market research firm Precedence Research believes the global cruise industry will grow at an ...

U.S. oil producers are grappling with geological limits to production growth as the country's top oilfield ages and produces ...

Palantir Technologies is an exciting company, but its stock is not a buy now. Investors should consider waiting for a far ...

The fund has beaten 99% of similar funds over the last 15 years.